BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

  June 25, 2025

   · 

  8 min read
• Press Releases

  Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

  June 25, 2025

   · 

  3 min read
• Press Releases

  Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

  June 25, 2025

   · 

  12 min read
• Press Releases

  Indivior Appoints Tony Kingsley to the Board of Directors

  June 25, 2025

   · 

  2 min read
• Press Releases

  Forte Biosciences Announces Proposed Public Offering

  June 25, 2025

   · 

  4 min read
• Press Releases

  Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

  June 25, 2025

   · 

  7 min read
• Press Releases

  Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

  June 25, 2025

   · 

  7 min read
• Press Releases

  Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

  June 25, 2025

   · 

  4 min read
• Press Releases

  Arcus Biosciences Announces New Employment Inducement Grants - June 24, 2025

  June 25, 2025

   · 

  1 min read
• 

  GLP-1

  Prescription Drug Sales Will Hit $1.75T By 2030 Thanks to GLP-1s: Evaluate

  Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be three times larger than what AbbVie’s blockbuster Humira ever achieved.

  June 25, 2025

   · 

  3 min read

   · 

  Annalee Armstrong